17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation. Issue 1 (28th June 2015)

• Record Type: Journal Article
• Authors: Wang, Jifeng; Li, Zhenyu; Lin, Zhiyuan; Zhao, Baobing; Wang, Yang; Peng, Ruixian; Wang, Meifang; Lu, Chunhua; Shi, Guowei; Shen, Yuemao
• Is Part Of: Cancer letters. Volume 362:Issue 1(2015)
• Page Start: 83
• Page End: 96
• Publication Date: 2015-06-28
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.03.025
• Languages: English
• ISSNs: 0304-3835

Abstract

<abstract abstract-type="author-highlights" id="ab0010"> <title id="st0010">Highlights</title> <sec> <p id="sp0010"> <list id="ulist0010"> <list-item id="u0010"> <label></label> <p id="p0010">This work indicates that 17-DMCHAG simultaneously downregulates the expression of androgen receptor and survivin.</p> </list-item> <list-item id="u0015"> <label></label> <p id="p0015">17-DMCHAG showed strong antitumor effects on LNCaP and DU-145 cell-xenografted nude mice with low hepatotoxicity.</p> </list-item> <list-item id="u0020"> <label></label> <p id="p0020">17-DMCHAG might provide a potential treatment approach for metastatic castration-resistant prostate cancer.</p> </list-item> </list> </p> </sec> </abstract>